CVA Family Office LLC Buys 142 Shares of Zoetis Inc. (NYSE:ZTS)

CVA Family Office LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 13.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,191 shares of the company’s stock after acquiring an additional 142 shares during the quarter. CVA Family Office LLC’s holdings in Zoetis were worth $206,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Bell Private Wealth Management LLC boosted its holdings in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Private Wealth Management Group LLC acquired a new stake in Zoetis in the 4th quarter worth about $33,000. Webster Bank N. A. raised its stake in Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Zoetis in the 4th quarter worth about $40,000. Finally, Neo Ivy Capital Management acquired a new stake in Zoetis in the 4th quarter worth about $40,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock traded down $0.39 during trading on Wednesday, reaching $184.90. 2,097,111 shares of the company were exchanged, compared to its average volume of 2,803,766. The company has a 50-day moving average of $175.81 and a two-hundred day moving average of $175.36. The company has a market capitalization of $84.37 billion, a price-to-earnings ratio of 35.70, a P/E/G ratio of 2.80 and a beta of 0.86. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.41 EPS. As a group, equities analysts predict that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date is Thursday, July 18th. Zoetis’s payout ratio is 33.33%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. BTIG Research assumed coverage on shares of Zoetis in a research note on Thursday, July 25th. They issued a “buy” rating and a $220.00 price objective for the company. The Goldman Sachs Group dropped their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Stifel Nicolaus lifted their price objective on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Piper Sandler restated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average target price of $214.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.